Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H10N6O.ClH |
| Molecular Weight | 218.644 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)\N=N\C1=C(N=CN1)C(N)=O
InChI
InChIKey=JTLLDOORGJVYPT-ASTDGNLGSA-N
InChI=1S/C6H10N6O.ClH/c1-12(2)11-10-6-4(5(7)13)8-3-9-6;/h3H,1-2H3,(H2,7,13)(H,8,9);1H/b11-10+;
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C6H10N6O |
| Molecular Weight | 182.1832 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Dacarbazine (DTIC), also known as imidazole carboxamide, is an antineoplastic agent, which is used in the treatment of metastatic malignant melanoma. In addition, this drug also is indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents. Dacarbazine works by methylating guanine at the O-6 and N-7 positions. Guanine is one of the four nucleotides that makes up DNA. The alkylated DNA strands stick together such that cell division becomes impossible. This affects cancer cells more than healthy cells because cancer cells divide faster. Dacarbazine is bioactivated in liver by demethylation to "MTIC" and then to diazomethane, which is an alkylating agent. Symptoms of anorexia, nausea, and vomiting are the most frequently noted of all toxic reactions. Over 90% of patients are affected with the initial few doses.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2311221 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | DTIC-DOME Approved UseDacarbazine for Injection USP is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection USP is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents. Launch Date1.70380804E11 |
|||
| Primary | DTIC-DOME Approved UseDacarbazine for Injection USP is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection USP is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents. Launch Date1.70380804E11 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.2 μg/mL |
750 mg/m² single, intravenous dose: 750 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
DACARBAZINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.8 μM × min |
750 mg/m² single, intravenous dose: 750 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
DACARBAZINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
41.4 min |
750 mg/m² single, intravenous dose: 750 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
DACARBAZINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
95% |
DACARBAZINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1000 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 1000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 1 times / 3 weeks Co-administed with:: Lenalidomide, p.o(5 mg/day; 14 days) Sources: Page: p.503, 504 |
unhealthy, 34–79 n = 3 Health Status: unhealthy Condition: Malignant melanoma Age Group: 34–79 Sex: M+F Population Size: 3 Sources: Page: p.503, 504 |
Disc. AE: Cerebral ischemia... AEs leading to discontinuation/dose reduction: Cerebral ischemia (grade 4, 33%) Sources: Page: p.503, 504 |
800 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 800 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 1 times / 3 weeks Co-administed with:: Lenalidomide, p.o(5 mg/day; 14 days) Sources: Page: p.503 |
unhealthy, 34–79 n = 16 Health Status: unhealthy Condition: Malignant melanoma Age Group: 34–79 Sex: M+F Population Size: 16 Sources: Page: p.503 |
DLT: Thrombocytopenia... Disc. AE: Thrombocytopenia... Dose limiting toxicities: Thrombocytopenia (grade 2, 6.25%) AEs leading todiscontinuation/dose reduction: Thrombocytopenia (grade 1, 6.25%) Sources: Page: p.503 |
1000 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 1000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 1 times / 3 weeks Sources: Page: p.5 |
unhealthy, 40–65 n = 45 Health Status: unhealthy Condition: Malignant melanoma Age Group: 40–65 Sex: M+F Population Size: 45 Sources: Page: p.5 |
Other AEs: Neutropenia, Fatigue... Other AEs: Neutropenia (grade 4, 2.2%) Sources: Page: p.5Fatigue (grade 4, 2.2%) |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Disc. AE: Leukopenia, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Leukopenia (grade 3-5) Sources: Thrombocytopenia (grade 3-5) Anemia (sometimes) Hematopoiesis impaired Hepatotoxicity (grade 3-5, 0.01%) Hepatic vein thrombosis (grade 3-5, 0.01%) Necrosis hepatocellular (grade 3-5, 0.01%) Anaphylaxis |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Disc. AE: Anemia, Leukopenia... AEs leading to discontinuation/dose reduction: Anemia (mild) Sources: Leukopenia (grade 3-5) Thrombocytopenia (grade 3-5) Hepatotoxicity (grade 3-5) Hepatic vein thrombosis (grade 3-5) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Cerebral ischemia | grade 4, 33% Disc. AE |
1000 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 1000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 1 times / 3 weeks Co-administed with:: Lenalidomide, p.o(5 mg/day; 14 days) Sources: Page: p.503, 504 |
unhealthy, 34–79 n = 3 Health Status: unhealthy Condition: Malignant melanoma Age Group: 34–79 Sex: M+F Population Size: 3 Sources: Page: p.503, 504 |
| Thrombocytopenia | grade 1, 6.25% Disc. AE |
800 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 800 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 1 times / 3 weeks Co-administed with:: Lenalidomide, p.o(5 mg/day; 14 days) Sources: Page: p.503 |
unhealthy, 34–79 n = 16 Health Status: unhealthy Condition: Malignant melanoma Age Group: 34–79 Sex: M+F Population Size: 16 Sources: Page: p.503 |
| Thrombocytopenia | grade 2, 6.25% DLT |
800 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 800 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 1 times / 3 weeks Co-administed with:: Lenalidomide, p.o(5 mg/day; 14 days) Sources: Page: p.503 |
unhealthy, 34–79 n = 16 Health Status: unhealthy Condition: Malignant melanoma Age Group: 34–79 Sex: M+F Population Size: 16 Sources: Page: p.503 |
| Fatigue | grade 4, 2.2% | 1000 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 1000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 1 times / 3 weeks Sources: Page: p.5 |
unhealthy, 40–65 n = 45 Health Status: unhealthy Condition: Malignant melanoma Age Group: 40–65 Sex: M+F Population Size: 45 Sources: Page: p.5 |
| Neutropenia | grade 4, 2.2% | 1000 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 1000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 1 times / 3 weeks Sources: Page: p.5 |
unhealthy, 40–65 n = 45 Health Status: unhealthy Condition: Malignant melanoma Age Group: 40–65 Sex: M+F Population Size: 45 Sources: Page: p.5 |
| Anaphylaxis | Disc. AE | 250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Hematopoiesis impaired | Disc. AE | 250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Hepatic vein thrombosis | grade 3-5, 0.01% Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Hepatotoxicity | grade 3-5, 0.01% Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Necrosis hepatocellular | grade 3-5, 0.01% Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Leukopenia | grade 3-5 Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Thrombocytopenia | grade 3-5 Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Anemia | sometimes Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Hepatic vein thrombosis | grade 3-5 Disc. AE |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Hepatotoxicity | grade 3-5 Disc. AE |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Leukopenia | grade 3-5 Disc. AE |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Thrombocytopenia | grade 3-5 Disc. AE |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Anemia | mild Disc. AE |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 2195.0 |
no | |||
Page: 2195.0 |
no | |||
Page: abstract |
yes | |||
Page: abstract |
yes | |||
Page: abstract |
yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Carcinogenicity of the antineoplastic agent, 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide, and its metabolites in rats. | 1975 Apr |
|
| Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin. | 1975 Nov |
|
| Fatal hepatic vascular toxicity of DTIC. Is it really a rare event? | 1988 May 15 |
|
| Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. | 2001 Aug |
|
| Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. | 2001 Dec |
|
| Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. | 2001 Feb |
|
| Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma. | 2001 Jul-Aug |
|
| [Correlation between functional capability and phenotypic characteristics of peripheral blood lymphocytes in patients with malignant melanoma]. | 2002 |
|
| Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha. | 2002 Dec |
|
| Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine. | 2002 Jan 1 |
|
| Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response. | 2002 Oct |
|
| IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC. | 2003 |
|
| Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. | 2003 Aug |
|
| Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme. | 2003 Feb 24 |
|
| Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. | 2003 Jul |
|
| Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. | 2003 Jun |
|
| Metastatic melanoma presenting as cardiac mass and hemobilia. | 2003 Mar |
|
| O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. | 2003 Oct 20 |
|
| [Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma]. | 2004 |
|
| Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations. | 2004 Apr 1 |
|
| A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. | 2004 Dec |
|
| Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma. | 2004 Dec |
|
| Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. | 2004 Dec |
|
| Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma. | 2004 Jun |
|
| Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. | 2004 Jun 1 |
|
| Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model. | 2005 Aug |
|
| Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. | 2005 Aug |
|
| Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. | 2005 Aug 1 |
|
| Amelanotic malignant melanoma of the esophagus: report of a patient with recurrence successfully treated with chemoendocrine therapy. | 2005 Jun |
|
| Clusterin regulates drug-resistance in melanoma cells. | 2005 Jun |
|
| Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cell cycle arrest. | 2005 Jun |
|
| Functional erythropoietin autocrine loop in melanoma. | 2005 Mar |
|
| Sarcomatoid renal cell carcinoma with a chromophobe component producing beta-human chorionic gonadotropin. | 2005 Sep |
|
| Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. | 2005 Sep 20 |
|
| Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study. | 2006 Aug-Sep |
|
| Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model. | 2006 Dec |
|
| Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group. | 2006 Nov |
|
| Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. | 2006 Oct 10 |
|
| Intralesional therapy of metastatic spreading melanoma with beta-interferon. | 2006 Sep |
|
| Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group. | 2007 Jul |
|
| Hemorrhagic cystitis in a patient receiving conventional doses of dacarbazine for metastatic malignant melanoma: case report and review of the literature. | 2007 Jun |
|
| Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. | 2007 Jun |
|
| CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma. | 2007 Nov |
|
| Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast. | 2007 Nov-Dec |
|
| Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. | 2007 Sep 15 |
|
| The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas. | 2008 Apr |
|
| Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma. | 2008 Feb |
|
| Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. | 2008 Feb 20 |
|
| Cerebellar dysfunction caused by procarbazine and consumption of excessive amount of bananas. | 2008 Jun |
|
| Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/c-Jun NH2-terminal kinase activation in human melanoma cells. | 2008 Mar |
Patents
Sample Use Guides
Malignant Melanoma: the recommended dosage is 2 to 4.5 mg/kg/day for 10 days. Treatment may be repeated at 4 week intervals
Hodgkin's Disease: The recommended dosage of Dacarbazine for Injection, USP in the treatment of Hodgkin’s disease is 150 mg/square meter body surface/day for 5 days, in combination with other effective drugs. Treatment may be repeated every 4 weeks.5 An alternative recommended dosage is 375 mg/square meter body surface on day 1, in combination with other effective drugs, to be repeated every 15 days
Route of Administration:
Intravenous
The effect of alkyating agent dacarbazine (DTIC) and imexon, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). Growth inhibition in vitro was additive with the two drugs. There was no effect on drug uptake or on the number of DNA strand breaks. There was a >75% reduction in cellular glutathione and cysteine with imexon but not DTIC. Co-administration of the two drugs in mice caused an increase in the area under the curve of both drugs, but the combination was not effective in reducing human A375 melanoma tumors in vivo.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 17 22:51:14 UTC 2022
by
admin
on
Sat Dec 17 22:51:14 UTC 2022
|
| Record UNII |
IBG90R0OVS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
IBG90R0OVS
Created by
admin on Sat Dec 17 22:51:14 UTC 2022 , Edited by admin on Sat Dec 17 22:51:14 UTC 2022
|
PRIMARY | |||
|
17925-90-5
Created by
admin on Sat Dec 17 22:51:14 UTC 2022 , Edited by admin on Sat Dec 17 22:51:14 UTC 2022
|
PRIMARY | |||
|
135565185
Created by
admin on Sat Dec 17 22:51:14 UTC 2022 , Edited by admin on Sat Dec 17 22:51:14 UTC 2022
|
PRIMARY | |||
|
21299-67-2
Created by
admin on Sat Dec 17 22:51:14 UTC 2022 , Edited by admin on Sat Dec 17 22:51:14 UTC 2022
|
NON-SPECIFIC STOICHIOMETRY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
